Klinomics Submits Securities Registration Statement for KOSDAQ Listing

[Asia Economy Reporter Eunmo Koo] Clinomics, a multi-omics-based early diagnosis and bio big data platform company, announced on the 6th that it submitted a securities registration statement to the Financial Services Commission on the 5th for listing on the KOSDAQ market.

Founded in 2011, Clinomics focuses on multi-omics-based products and services, as well as liquid biopsy-based cancer diagnosis and screening as its core businesses. The company passed the technology evaluation by receiving an A grade from two specialized technology evaluation institutions in June.

The company's core technology, multi-omics, is a technique that studies and analyzes multiple omics data such as genomics, transcriptomics, and epigenomics. It can be applied to various underlying diseases and enables precision medicine through integrated analysis.

Clinomics established a local subsidiary in the United States, a leading market in genomics, in 2017, and last year established a subsidiary in the United Kingdom to enter the European market. The company plans to establish subsidiaries in regions such as Asia and South America in the future to increase global technology transfer and product supply.

Byungchul Kim, co-CEO of Clinomics, stated, “We decided to list on the KOSDAQ market to expand the company's main business and strengthen global competitiveness,” adding, “The proceeds from the public offering will be used for facility investment, research and development, and marketing expenses.”

The total number of shares offered by Clinomics is 2,288,000, with a desired price band of 12,800 KRW to 16,300 KRW per share. Demand forecasting will be conducted over two days on the 28th and 29th to finalize the offering price, followed by a two-day general public subscription on the 3rd and 4th of next month. The listing is scheduled for November, with Daishin Securities as the lead underwriter.

This content was produced with the assistance of AI translation services.